Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447499 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT00447499: Completed Phase 3 study, sponsored by Ipsen.
NCT00447499 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 59 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00447499, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
Primary Outcome
The primary efficacy endpoint was the percentage of patients (Switch and other) or their partners who were competent to self-administer lanreotide at the end of the study (Week 24/Early Termination), as assessed by the Assessment of Competence Questionnaire (0 = 'No' and 1 = 'Yes').
Interventions
- DRUG Somatuline Autogel (lanreotide acetate)
- BEHAVIORAL Home administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
What the finished NCT00447499 record still lists
NCT00447499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Somatuline Autogel (lanreotide acetate) is the first listed.
NCT00447499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00447499 about?
NCT00447499 is a clinical study titled "Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel". The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
What is the current status of trial NCT00447499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2007-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00447499?
The interventions under investigation include: Somatuline Autogel (lanreotide acetate) (DRUG), Home administration (BEHAVIORAL).
Who is sponsoring clinical trial NCT00447499?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00447499's enrollment target sits among peer trials
59 1824th of 2000 higher than 176 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia